Published in Expert Rev Mol Diagn on February 21, 2015
CIN III lesions and regression: retrospective analysis of 635 cases. BMC Infect Dis (2015) 0.78
JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix. Oncotarget (2015) 0.75
VEGF +936 C/T Genetic Polymorphism in Patients with Cervical Dysplasia. Anal Cell Pathol (Amst) (2016) 0.75
Association between folate status and cervical intraepithelial neoplasia. Eur J Clin Nutr (2016) 0.75
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Burden of adhesions in abdominal and pelvic surgery: systematic review and met-analysis. BMJ (2013) 2.53
Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. Am J Obstet Gynecol (2007) 1.80
Ovarian cancer. Crit Rev Oncol Hematol (2006) 1.64
Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol (2010) 1.47
Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol (2009) 1.44
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
Management of borderline ovarian neoplasms. J Clin Oncol (2007) 1.15
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer (2011) 1.14
High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol (2006) 1.11
Chemotherapy for recurrent cervical cancer. Gynecol Oncol (2007) 1.03
Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol (2011) 1.01
Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecol Oncol (2008) 1.00
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer (2012) 0.98
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat (2008) 0.97
Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol (2012) 0.96
The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer (2010) 0.95
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. Gynecol Oncol (2012) 0.95
Angiosarcomas of primary gynecologic origin: a clinicopathologic review and quantitative analysis of survival. Int J Gynecol Cancer (2014) 0.95
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer (2006) 0.94
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer (2012) 0.94
Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol (2003) 0.93
Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol (2010) 0.93
Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol (2005) 0.93
Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis (2011) 0.93
Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: first report on the technique used in 5 patients. Acta Obstet Gynecol Scand (2008) 0.92
Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Res (2012) 0.92
Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents. BMC Public Health (2012) 0.91
The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol (2007) 0.90
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. Oncologist (2008) 0.89
Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer (2013) 0.89
Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer (2013) 0.89
Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: a study from the population-based PROFILES registry. Gynecol Oncol (2013) 0.89
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. BMC Cancer (2013) 0.89
Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol. J Clin Endocrinol Metab (2012) 0.89
Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs. no adjuvant regional treatment in early-stage endometrial carcinoma: a large population-based study. Gynecol Oncol (2012) 0.89
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. Mol Cancer (2012) 0.88
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer (2012) 0.88
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res (2002) 0.88
Cervical intraepithelial neoplasia grade 3 lesions can regress. APMIS (2007) 0.88
Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des (2012) 0.87
Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression. J Immunother (2011) 0.87
Evaluation of adnexal masses with three-dimensional ultrasonography. Obstet Gynecol (2006) 0.87
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer (2014) 0.87
Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. Int J Gynecol Cancer (2015) 0.86
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. BMC Cancer (2008) 0.86
Oncology providers' evaluation of the use of an automatically generated cancer survivorship care plan: longitudinal results from the ROGY Care trial. J Cancer Surviv (2013) 0.86
A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass. Gynecol Oncol (2013) 0.86
Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol (2012) 0.85
Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int J Gynecol Cancer (2011) 0.85
Survivorship Care Plans to inform the primary care physician: results from the ROGY care pragmatic cluster randomized controlled trial. J Cancer Surviv (2014) 0.85
Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol (2010) 0.85
Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther (2011) 0.84
Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys (2006) 0.84
The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Hum Pathol (2010) 0.83
Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol Oncol (2009) 0.83
Galectin-9 activates and expands human T-helper 1 cells. PLoS One (2013) 0.83
Molecular biomarkers in cervical cancer diagnosis: a critical appraisal. Expert Opin Med Diagn (2013) 0.83
Use of biomarkers in the evaluation of CIN grade and progression of early CIN. Methods Mol Med (2005) 0.83
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer (2009) 0.82
Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles. Clin Cancer Res (2005) 0.82
Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev (2010) 0.82
Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. BMC Cancer (2012) 0.82
Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer (2012) 0.82
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer (2014) 0.82
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer (2011) 0.81
Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands. BMC Public Health (2014) 0.81
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol (2012) 0.80
Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. Am J Surg Pathol (2005) 0.80
The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res (2009) 0.80
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer. Int J Gynecol Cancer (2014) 0.79
Should we centralise care for the patient suspected of having ovarian malignancy? Gynecol Oncol (2011) 0.79
Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev (2014) 0.79
The management of borderline tumours of the ovary. Curr Opin Oncol (2006) 0.79
Proteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS. Methods Mol Biol (2011) 0.79
Predictive testing of early CIN behaviour by molecular biomarkers. Cell Oncol (2005) 0.79
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Mol Pharm (2010) 0.79
Translabial three-dimensional ultrasonography compared with magnetic resonance imaging in detecting levator ani defects. Obstet Gynecol (2014) 0.79
Multiple miscarriages are associated with the risk of ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition. PLoS One (2012) 0.78
The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy (2015) 0.78
A family history questionnaire improves detection of women at risk for hereditary gynecologic cancer: a pilot study. Fam Cancer (2014) 0.78
Vaccine-based clinical trials in ovarian cancer. Expert Rev Vaccines (2011) 0.78
Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. Int J Gynecol Cancer (2012) 0.78
Is three-dimensional ultrasonography of additional value in the assessment of adnexal masses? Gynecol Oncol (2007) 0.78
Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study. Infect Agent Cancer (2012) 0.78
Application of proteomics in ovarian cancer: which sample should be used? Gynecol Oncol (2009) 0.77
Sentinel node in ovarian cancer: study protocol for a phase 1 study. Trials (2013) 0.77